JP Morgan Chase
JNCE

JP Morgan Chase’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

JP Morgan Chase’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-323,500
Closed -$7.23M – 5748
2018
Q1 		$7.23M Buy
+323,500
New +$7.18M ﹤0.01% 2272

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase's JNCE Position: Q2 2023 in Review

JP Morgan Chase sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 1,136,847 shares — an estimated $2.1M sold.

JP Morgan Chase first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $3.38M in Q1 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • JP Morgan Chase reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1,136,847 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.1M.
  • JP Morgan Chase first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
  • JP Morgan Chase's Jounce Therapeutics, Inc. Common Stock position peaked at $3.38M in Q1 2018.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.